U.S. Stock Night Market Movements

Addex Therapeutics rose 19.91% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Eli Lilly rose 0.26% in the night market. Based on recent key news:

1. On August 19, Eli Lilly's stock price increased by 5.3%, closing at $1290 per share, reaching a historical high. The core driver of the company's performance comes from the GLP-1 diabetes and weight loss drug matrix, with Q2 revenue and profit significantly exceeding market expectations, and the company simultaneously raised its full-year performance guidance. Source: Daily Economic News

2. On August 20, Eli Lilly signed a cooperation agreement with Amplitude Therapeutics to jointly develop a trans-amplifying RNA vaccine candidate for infectious diseases. The financial terms of this cooperation were not disclosed, and the two companies will initially focus on vaccine projects with high unmet medical needs. Source: Viewpoint Network

3. On August 19, Eli Lilly's stock price rose by 3.6%, closing at $1225.73. The company's strong financial performance prompted several analysts to raise their target prices. BMO Capital Markets raised Eli Lilly's target price to $1400, while Wells Fargo raised it to $1330. Source: MarketBeat The innovative drug sector is welcoming investment opportunities, with a dense release of clinical data throughout the year.

Novo Nordisk rose 1.26% in the night market. Based on recent key news:

1. On August 19, Novo Nordisk began testing low-dose Wegovy oral tablets in a new obesity study. This move demonstrates the company's ongoing innovation capability in the weight loss drug market, potentially boosting investor confidence and driving up stock prices. Source: Bloomberg

2. On August 19, Novo Nordisk's CEO stated that the demand for the Wegovy weight loss oral drug is offset by lower prices, but the rapid adoption in the U.S. market remains a major growth driver. This news may enhance market expectations for the company's future growth. Source: Company Statement

3. On August 20, due to a shortage of Glucagon injection formulations, Novo Nordisk plans to import equivalent drugs through special projects to maintain supply. This move shows the company's proactive response in supply chain management, which may have a positive impact on stock prices. Source: Zhitong Finance The weight loss drug market is highly competitive, with significant potential for growth.

Merck rose 0.60% in the night market. Based on recent key news:

1. On August 20, Merck's personalized mRNA cancer vaccine developed in collaboration with Moderna achieved positive results in Phase III clinical trials, driving Merck's stock price up by 12.6%. The vaccine showed positive results in reducing the risk of melanoma recurrence, enhancing market confidence in Merck's future product line. Source: Economic News Agency

2. On August 21, UBS raised Merck's target price from $145 to $175, reflecting analysts' optimistic expectations for Merck's future growth potential Source: Benzinga

On August 19, Merck's stock price hit a record high, rising 9.6%, reflecting the market's positive response to its recent research and development achievements. Source: Hong Kong Economic Journal Financial News The pharmaceutical sector is significantly influenced by AI trading rotation, with noticeable capital inflows